1. KAID-OMAR Z., DAUDON M., ATTAR A., SEMMOUD A., LACOUR B., ADDOU A.
Corrélation entre cristalluries et composition des calculs. Progrès en Urologie 1999 ;9 : 633-641.
2. DJELLOUL Z., DJEllOUL A., BEDJAOUI A., KAID OMAR Z., DAUDON M., ADDOU A. Lithiase urinaire dans l’Ouest Algérien : Etude et analyse de 1354 calculs urinaires en relation avec la composition chimique, l’âge et le sexe des patients. Progrès in Urologie Progrès en Urologie., 2006; 16: 328-335.
3. BELHADJI A., KACEM B., KAID OMAR Z., DAUDON M., ADDOU M. Etude des relations entre infection urinaire et lithiase rénale dans l’Ouest algérien. L’eurobiologiste 2004 ; Tome XXXV, N° 269, p.5.
4. DAUDON M., HENNEQUIN C., BADER C., JUNGERS P., LACOUR B., DRUEKE T.
Inhibiteur de la cristallisation dans l’urine. Actualité néphrologique de l’hôpital Necker, Paris, Flammarion, Médecines-Sciences., 1994; Pp : 176
5. GRASES F., SÖHNEL O., VILACAMPA AI., MARCH JG. Phosphates precipitating from artificial urine and fine structure of phosphate renal calculi. Clinica Chimica Acta., 1996; 244: 45-67.
6. GRASES F., COSTA B. A study of factors affecting calcium oxalate crystalline aggregation.
Brj, Urol., 1990; 66: 240-244.
7. GRASES F., GILL J.J., CONTE A. Urolithiasis inhibitors and calculus nuclation. Urol Res., 1989; 17: 163-166
8. HENNEQUIN C. Correlation entre les concentrations molaires relatives du calcium, de l’oxalate, du citrate et du magnésium et le risque cristallogène dans les urines et in vitro.
PROJET D’ETUDE janvier 1995.
9. DRIOUCH A., DJELLOUL A., KAID OMAR Z.,SEMMOUD A., RAIS A., ADDOU A., Optimized experimental design for the inhibition of calcium oxalate using a turbidimetrical model.Asia-Pac.J.Chem. Eng.2008 ;3 :425-431.
10. JUNGERS P., RIEU P., MERIA P., KNEBELMANN B., DAUDON M. Lithiase d’infection. L’eurobiologiste 2001; 34(254) : 23-28.
11. DRIOUCH A., Etude de l'inhibition des cristaux oxalo calciques dans l'urine artificielle.
Thèse de doctorat en Science. Option Chimie. Université de Mostaganem. 2005, pp: 136.
12. JUNGERS P., DAUDON M., CONORT P. Lithiase rénale : diagnostic et traitement 1 vol, 1999, 256 pages, Paris, Flammarion Médecine-Sciences.
13. COE FL, PARKS JH. Nephrolithiasis. Pathogenesis and treatment. 2nd ed, Chicago, Year Book Medical, Publishers, 1988.
14. HOLMGREN K, DANIELSON 8G, FELLSTROM B, LJUNGHALL S, NIKLASSON F, WIKSTROM B. The relation between urinary tract infections and stone composition in renal stone formers. Stand JUrol Nephrol 1989 ; 23 :131-136.
15. WONG HY, RIEDL CR, GRIFFITH OP. Medical mangement and prevention of struvite stones. In: COE FL, FAVUS MJ, PAK CYC, PARKS JH, PREMINGER GM (eds), Kidney Stnriees. Medical and Surgical Management. Lippincott-Raven Publishers, Philadelphia, 1996, pp. 941-950.
16. MAURICE.ESTEPA L, LEVILLAIN P, LACOUR B, DAUDON M. Crystalline phase differentiation in urinary calcium phosphate and magnesium phosphate calcul. ScondJ Urol Nephrol 1999 ; 88 : 299-305.
17. OUSSAMA A., KZAIBER F., MERRNARI A., HILIMI A., SEMMOUD A., DAUDON M. Analyse des calculs urinaires de l’adulte dans le Moyen Atlas Marocain par spectrophotométrie IRTF. Progrès en urologie (2000). 10. 404-450.
18. M.DAUDON, B.BOUNXOUEL, F.SANTA CRUZ. Composition des calculs observés aujourd’hui dans les pays non industrialisés. Progré en Urologie 2004, 14,1151-1161.
19. JUNGERS. P. Les calculs urinaires. Ed Herman.Paris, ISBN,1987,270.56.60.712.
20. DAUDON M. Mécanisme de cristallisation dans l’urine. Nephrologie 1995 ; 16 : 313- 315.
21. DAUDON M., DONSIMONI R., HENNEQUIN C., FELLAHI S., LE MOEL G., PARIS M., TROUPEL S., LACOUR B. Sex-and age- related composition of 10617 calculi analysed by infrared spectroscopy. Urol Res. 1995, 23 : 319-326.
22. JUNGERS P., DAUDON M., LE DUC A. Lithiase urinaire. 2-257-10212-6. Ed, Médecine-Sciences. Flammarion, Paris., 1989; PP. 136-350.
23. GAULT MH., ROBERTSON WG., SENCIALL DR. The oxalate: phosphate ratio in urinary tract calculi by infrared analysis. Clin Chim Acta., 1987; 166: 103-105.
24. DAUDON M., DORE B. Cristallographie des calculs urinaires. Aspects néphrologiques et urologiques. Elsevier Paris Ency, Médi, Chir, 18-104-A., 1999; 25: 1-16.
25. BARBEY F., JUNGERS P., DAUDON M. Lithiase phosphocalcique: Définition, fréquences, facteurs de risques et Particularités évolutives ; Feuillets de Biologie., 2001;
Vol. XXXII –N° 243; 33-36.
26. FRANCI MD., WEBB NC. Hhdroxyapatite formation from hydrated calcium monohydrogen phosphate precursor. Calcif Tiss Res 1971; 6: 335-342.
27. PAK CYC. Potentiel etiologic role of brishite in the formation of calcium (renal) stones. J Crystal Growth 1981; 53: 202-208.
28. CHENG PT. Magnesium inhibits octacalcium phosphate and apatite but promotes whitlockite and brushite formation. Urol Res 1988; 16: 222.
29. DAUDON M., DONSIMONI R., HENNEQUIN C., FELLAHI S., LE MOËL G., PARIS M.
Sex- and age-related composition of 10617 calculi analyzed by infrared spectroscopy. Urol Res., 1995; 23: 319-326.
30. BOYER H. Infrared spectrometry and raman microbe in the analysis of urinary Kedny Int., 1983; 23: 842-850.
31. NANCOLLAS GH, ET KOUTSOUKOS PG. Calcium phosphate nucleation and growth in solution. Prog Crystal Growth Charact., 1980; 3: 77-102.
32. WERNESS PG., BERGET JH., SMITH LH. Crystalluria. J Crystal Growth., 1981; 53: 166- 181.
33. PAK CYC., SAKHAEE K., CROWTHER C., BRINKLEY L. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Intern Med., 1980; 93: 36-39.
34. PAK CYC. Kidney stones. Lancet., 1998; 351: 1797-1801.
35. KAID-OMAR Z. Etude multiparamétrique de la lithiase urinaire dans l'Ouest Algérien.
Thèse de doctorat d'Etat en chimie., 1999.
36. NGUYEN QD., DAUDON M. Infrared and Raman Spectra of Calculi. Edition Scientifique et Médicale Elsevier., 1997; ISBN : 2-84299-003.
37. BARIETY M., BONNIOT R., MOLINE J. Abrégés sémiologie médicale. 7 ème Ed Paris., 1990; Pp: 546.
38. DAUDON M., BADER CA., JUNGERS P. Urinary calculi: Review of classification methods and correlations with etiology. Scanning Microscopy., 1993; 7: 1081-1106.
39. LEUSMANN DB. A classification of urinary calculi with respect to their composition and micromorphologiy. SCAND J Urol., 1991; 25: 141-150.
40. LIBSRAY.BA.Urinary tract infections in men.Epidemiology pathophysiology diagnosis and treatment Ann. Int Med 1989, 110 ;138-150.
41. SUTOR DJ. WOOLEY FE.Identification standards for human urinary calculus componets.Br J Urol 1970, 42:386-388.
42. BONNIER. L, COPERRE.H, SABATIER JC, SEFFERT P. Néphrologie.Ed Paris, 1990. P 295.
43. AZELE.F. Bactériologie médicale à l’usage des étudiants en médecine 1999. Ed C et R, 14 eme éddition. Paris, 116.
44. AHLSTRAND.C, TISELUIS. LARSON.I.Studies on crystalluria in calcium oxalate stone formers. Urol 1984, 12:103-106.
45. DAUDON M. Cristallurie, Aspects pratiques et interprétations /I. Feuillet de Biologie, 1987, 28 :25-40.
46.DAUDON M. Cristallurie, Aspects pratiques et interprétations /II. Feuillet de Biologie, 1987, 28 :14-47.
47. DAUDON M., REVEILLARD R.J. calculs urinaires. Fiche pratique biol (1985), 3: 21- 27
48. MEYER A, DEIANA J, LECLERC H. Cours de microbiologie 1995. Ed Doin. Paris 365.
49. DJALOUAT K. Le diagnostic biochimique bactérien 1990. Ed Science et technique,118.
50. NOEL.JOFIN.J, LEYRAL.G. Microbiologie technique 1997. Ed CRDP, 247.
51. MARCHAL.N, BOURDOU.JI, BIMET P 1988. Laboratoire de microbiologie médicale.Ed Doin.Paris
52. LAPRENT.JP, GOURGAUD.ML. Memento technique de microbiologie 1997. 3eme Ed. Paris. 1039.
53. DAUDON M, BADER CA, JUNGERS P. Urinary Calcuti: Review of classification methods and correlations with etiology. Scanning Microsc 1993 ; 7 : 1081-1106.
54. DAUDON M. Comment analyser un calcul et comment interpréter le résultat.
L'Eurobiologiste 1993 ; 27 : 35-46.
55. VALKENBURG HA. Epidemiology of urinary tract infections. Eur Urol 1987 ; 13 (suppl. 1) : 5-8.
56. BOSCIA JA, KOBASA WD, KNIGHT RA, ABRUTYN E, LEVÏSON ME, KAYE D.
Epidemiology of bacteriuria in an alderly ambutatory population. Am J Med 1986 ; 80 : 208-214.
57. RICCABONA M. Urinary tract infections in children. Curr Opin Urol 2003 ; 13 : 59- KUNIN CM. Detection, prevention and management of urinary tract infections. 4ème édition. Lea & Febiger, Philadetphia, 1987.
58. LIPSKY BA. Urinary tract infections in men. Epidemiology, pathophysiotogy, diagnosis and treatment. Mn Int Med 1989 ; 110 : 138-150.
59. KUNIN CM. Detection, prevention and management of urinary tract infections. 4ème édition. Lea & Febiger, Philadetphia, 1987.
60. UNCU Y, UNCU G, ESMER A, BILGEL N. Should asymptomatic bacteriuria be screened in pregnancy ? Clin Exp Obstet Gynecol 2002 ; 29 : 281-285
61. HUMMERS-PRADIER E, KOCHEN MM. Urinary tract infections in adult general practice patients. Br J Gen Pract 2002 52 : 752-761(normalement 67)*****
62. DAUDON M. Lithiase urinaire et infection. L'Eurobiologiste 1990 ; 24 : 257-264.
63. JUNGERS P, RIEU P, MÉRIA P, KNEBELMANN B, DAUDON M. Lithiase d'infection. L'Eurobiologiste 2001; 34 (254): 23-28.
64. GRIFFITH DP, OSBORNE CA. Infection (urease) stones. Miner Electrolytr Metab 1987; 13: 278-285.
65. SABINSKI F , IEUSMANN DB. Potentiat contribution of optionat urease-positive bacteria to idiopathic urinary calcium stone formation. I . Expression of urease activity in bacteria from the urinary tract that are commonty classsified as urease-negative. Urol Res 1996 ; 24 : 51-54.
66. EDIN-LIIJEGREN A, HEDELUN HH, GRENABO L, PETTERSSON S. Impact of Escherichia coli on urine citrate and urease-induced crystatlization. Scann Microsc 1995 ; 9 : 901-905.
67. BROWN BJ, ASINOBI A0, FATUNDE 0J, OSINUSI K, FASINA NA. Antimicrobial sensitivity pattern of organisms causing urinary tract infection in children with sickte cet [anaemia in Ibadan, Nigeria. West Afr J Med 2003 ; 22 : 110-113.
68. MANSOURI S, SHAREIFI S. Antimicrobial resistance pattern of Escherichia coti causing urinary tract infections, and that of human fecat flora, i n the southeast of Iran.
Microb Orug Resist 2002 ; 8 : 123-128.
69. DRISSIA DIALLO. Cultivation, post harvesting and pocessing technologies of MAPs in develloping countries, Bamako, 25-29 july 2005.
70. MARJORIE MURPHEY COWAN. Plant products as antimicrobial agents.Clinical Microbiologie Revieus, Oct 1999, p 564-582.
71. HENNEBELLE T.; SAHPAZ S. ; BAILLEUL F. Polyphénols végétaux, sources, utilisations et potentiel dans la lutte contre le stress oxydatif. Phytotherapie(2004), N°
1: 3-6.
72. ISERIN P. Encyclopédie des plantes médicinales. Identification-Préparation-Soins.
(2001), P 335.
73. SANOGO ROKIA, DIALLO DRISSA, DIARRA SEYDOU, EKOUMOU COLETTE, BOUGOUDOGO FLABOU. Activite antibacterienne et antalgique de deux recettes traditionnelles utilisées dans le traitement des infections urinaires et la cystite au Mali.
Mali médical 2006 TXXI.
74. PARIS M.; HURABIELLE M. Abrégé de matière médicale pharmacognosie. tomes I,
Masson.M, Paris. 2001, P 339.
75. PARIS R.R. ; MOYSE H. Matière médicale. tome 1 Masson m, 2 ème édition, Paris (1976), P 419.
76. BRUNETON J. Pharmacognosie et Phytochimie des plantes médicinales. 2ème édition, Paris. (1993), P 914.
77. BAHORUN T, GRESSIER B, TROTIN F, BRUNET C, DINE T. Oxygen species scravening activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. Arznieminihel-forshung / Dryg Research 46 II pp 1086 -1089.
78. WICHTL M., ANTON R. Plantes thérapeutiques. 2ème Ed., 1999; 43: 140-216.
79. ROGUET DIDIER. De la plante au médicament, Genève. Conservation et Jardins Botaniques de Genève .1988.
80. ALILOU. H, B. CHEBLI, L.M. IDRISSI HASSANI, R. ROUHI, F. MELLOUKI,M.
AKSSIRA. Activité antifongique de Bubonium odorum (Asteracées) sur des champignons pathogènes d'agrumes. Reviews in Biology and Biotechnology.Vol.6, january 2007.pp.20-24.
81. SUBIZA J, SUBIZA JL, HINOJOSA M. Anaphylactic reaction after the ingestion of chamomile tea: a study of cross-reactivity with other composite pollens. J Allergy Clin Immunol. 1989,84: 353-58.
82. BABA AISSA F. Les plantes médicinales en Algérie. Ed, Bouchène et AD. Diwan, Alger., 1991, 71 : 119-173.
83. CALISKANER Z, KARAAYVAZ M, OZTURK S. Misuse of a herb: stinging nettle (Urtica urens) induced severe tongue oedema. Complement The Med. 2004 Mar;
12(1):57-8.
84. VINCENT RODZKO " Abécédaire de Phytothérapie ". 1999-2000.
85.PAULETTE VANIER. L’orge au fil du temps. Usages Culinaire. Ecologie et Environnement,15 Décembre 2004.
86. N.DOHO. Screening phytochimique d’une épidémique Ibéro-Marocaine, Thymeleae Lythroides, Bull.Soc.Pharm. Beaurdeaux. 2003, 142, 61-78.
87. A. BOUQUET et A. FOURET. Recherches chimiques préliminaires sur les plantes médicinales du Congo-Brazzaville. Estrato de Fitotérapia- Vol-XLVI-N4.1975.
88. A. M DIALLO. Etude des plantes medicinales de niafunke(region de Tombouctou), phytochimie et pharmacologie de Maerua crassifolia, (Capparidacée). Thése de Doctorat en Pharmacie.2005
89. DRISSIA DIALLO, ROKIA SONOGO. Etude des constituants des feuilles de Ziziphus mauritania Lam. (Rhamneceae),utililisées traditionellement dans le traitement du diabète au Mali. CR Chimie 7, 2004, 1037-1080 ELSIVIER
90. M. C MATHABE, R.N.NIKOLOVA. Antibactérial activities of medicinales plants used for the treatment of diarrhoea in Limpopo Province, South Africa. Journal of Ethnopharmacology 105, 2006, 286 -293.
91. JOHN U W. Antimicrobial compounds 1983. Ed J.A. CALLOW. P238-256
92. M.T. CHOMNAWANG. S, SURASSMO.V.S. NUKOOLKARN. Antimicrobial effects of Thai medicinal plants against acne-inducing bacteria, 2005. Journal of Ethnopharmacology 101 330–33
93.SHIN.S., KIM. J. H. In vitro inhibitory activities of essential oils from two Korean Thymus species against antibiotic-resistant pathogens, 2005. Arch. Pharm. Res.8,897-901.
94. SCALBERT, A. Antimicrobial properties of tannins. Phytochemistry 1991 ; 30 ; 3875- 83.
95. TOMÁS-BARBERAN, F., INIESTA-SAN MARTIN, E., TOMÁS-LORENTE, F. AND RUMBERO, A. Antimicrobial phenolic compound from three Spanish Helichrysum species. Phytochemistry 1990; 29; 1093-5.
96. LUTETE T KAMBU K. NTONDELE D. CIMANGA K. ET LUKI N : Antimicrobial activity of tannins. Fitoterapia 1994 ; 65 ; 276-8
97. REES SB AND HARBORNE JB. The role of sesquiterpene lactones and phenolics in the chemical defence of the chicory plant 1985. Phytochem. 24 : 2225 – 2231.
98. UNLU G.V., CANDAN F., SOKMEN A., DAFERERA D., POLISSIOU M., SOKMENM., DONMEZ E., TEPE B. (2003) Antimicrobial and antioxidant activity of the essential oil and methanol extracts of Thymus pectinatus. Fish. et Mey. Var. pectinatus (Lamiaceae), J. Agr. Food Chem.51, 63–67.
99. N. AMEZIANE, H. BOUBAKER, H. BOUDYACH, F.MSANDA, A. JILAL, A. AIT BENAOUMAR. Antifungal activity of Moroccan plants against citrus fruit pathogens.
INRA, EDP Sciences, 2007
100. BRUNETON J. Pharmacognosie, Phytochimie, Plantes médicinales 1993. Paris ; Éd Technique et Documentation Lavoisier.
101. IMBALI E.S., IBRAHIM K.E., AHMED B.M., ABULFUTUH J.M., HULBERT P.
Chemical characterization of tamarind bitter principle, tamarindineal. Fitoterapia 1992 ; 6 (63) ;537-8.
102. ALI M.S., AHMAD V.U., AZHAR I., USMANGHANI K. Chemotropism and antimocrobial activity of Tamarindus indica. Fitoterapia 1998 ; 1 (64) : 43-6.
103. O.M.S. Rapport de l’O.M.S sur les critères de l’évolution. (1993).
104. J.L.RIOS, M.C.RECIO. Medicinal plants antimicrobial activity 2005. Journal of Ethnopharmacology, 80-84.
105. JOHNU.W.Antimicrobial compounds.1983.Ed.CALLOW.p2386256.
106. RANDHAWA MA., AL-GHAMDI MS. A review of the pharmaco-therapeutic effects of Nigella sativa. Pakistan J. Med. Res., 2002, 41.
107. YOKOZAWA T., SUZUKI N., ZHENG PD., OURA H., NISHIOKA I. Effect of orally administered rhubarb extract in rats with chronic renal failure. Chem Pharm Bull.
1984, 32 : 4506-4513.
108. ZHANG G., EL NAHAS AM. The effect of rhubarb extract on experimental renal fibrisis. Nephrol Dial Transplant., 1996, 11 : 186-190.
109. KOIDE T., YAMAGUSHI S., UTSUNOMIYA M., YOSHIOKA T., SUGIYAMA K.
The inhibitory effect of Kampou extracts on in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. Int J Urol., 1995, 2 : 81-86.
110. OHKAWA T., EBISUNO S., KITAGAWA M., MORIMOTO S., MIYAZAKI Y.
Rice-bran treatment for hypercalciuric patients with urinary calculus disease. J Urol., 1983, 129 : 1009-1011.
111. OHKAWA T., EBISUNO S., KITAGAWA M., MORIMOTO S., MIYAZAKI Y., YASUKAWA S. Rice-bran treatment for patients with hypercalciuric stones : Experimental and clinical studies. J Urol., 1984, 132 : 1140-1145.
112. GRASES F., MASAROVA L., COSTA-BAUZA A., MARCH JG., PRIETO R., TUR JA. Effect of Rosa Canina infusion and magnesium on the urinary risk factors of calcium oxalate urolithiasis. Planta Med., 1992, 58 : 509-512.
113. GRASES F., MARCH JG., RAMIS M., COSTA-BAUZA A. The influence of Zea Mays on urinary risk factors for kidney stones in rats. Phytotherapy Res., 1993, 7 : 146- 149.
114. GRASES F., RAMIS M., COSTA-BAUZA A, JG March : Effect of Herniaria hirsuta and Agropyron repens on calcium oxalate urolithiasis risk in rat. J Ethnopharmacol. 1995, 45 : 211-214.
115. VIEL TA., DOMINGOS CD., MONTEIRO AP., LIMA-LANMAN MTR., LAPA AJ., SOUCCAR C. Evaluation of the antiurolithiatic activity of the extract of Costus spiralis Roscoe in rats. J Ethnopharmacol., 1999, 66 : 193-198.
116. ATMANI F., KHAN SR. Effect of an extract from Herniaria hirsuta on calcium oxalate crystallisation in vitro. BJU INT., 2000, 85 : 621-625.
117. BERLAND Y., OLMER M., Boistelle R., BARLATIER A. Influence respective du calcium et de l’oxalate sur la cristallisation des oxalates de calcium dans l’urine.Nephrol.;
1984; 5 :175-179.
118. WERNESS PG., BROWN CM., SMITH LH., FINLAYSON B. Equil2.A Basic computer program for the calculation of urinary saturation. J.Urol., 1985 ;134 :1242- 1244.
119. MARANGELLA M., DANIELLE P.G., RONZANI M., SONEGO S., LINARI F.
Urine saturation with calcium salts in normal subjects and idiopathic calcium stone- formers estimated by an improved computer model systems. Urol. Res. 1985,13,189-193.
120. LIBAGUE A., FINI M., ROBERTSON WG. Infuence of urine on « in vitro »
crystallization rate of calcium oxalate : determination of inhibitory activity by a 14C- oxalate technique.Clin.Chim.Acta., 1979 ;98 : 39-46.
121. NGUVEN QD., DAUDON M. Infrared and Raman Spectra of Calculi. Edition Scientifique et Médicale Elsevier., 1997; ISBN: 2-84299-003-X.
122. HENNEQUIN C., LALANNE V., DAUDON M., LACOUR B., DRUCKE T. A new approach to studying inhibitors of calcium oxalate crystal growth. Urol Resc., 1993; 21:
101-108
123. HESS B. Tamm- Horsfall glycoprotein - inhibitor or promotor of calcium oxalate monohydrate crystallization processus. Urol Res., 1992; 20:83.
124. ACHILLES W., ULSHAFER B, Investigation on the potentiel role of magnesium in the pathogenisis and traitment of calcium urolithiasis. Mag Bull,6,276-279.
125. DESMARS JF., TAWASHI R. Dissolution and growth of calcium oxalate monohydrate. I. Effect of magnesium and pH. Biochim Biophys Acta, 1973,313,256-267.
126. KOHRI K., GARSIDE J., BLACKLOCK NJ. The role of magnesium in calcium oxalate urolithiasis. Br J Urol., 1986; 61: 107-115.
127. MEYER JL., THOMAS WC. Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. J. Urol, 1982,128,1376-1378.
128. ANTINOZZI PA., BROWN CM., PURICH DL. Calcium oxalate monohydrate crystallization: citrate inhibition of nucleation and growth steps. Journal of Crystal Growth., 1992; 125,215-222
129. HESS B. The role of Tamm- horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processus. Scanning Microsc., 1991; 5 : 689-96
130. NAKAGAWA Y., ABRAM V., COE FL. Isolation of calcium oxalate crystal growth inhibitors from rat kidney and urine. Am J Physiol., 1984; 247: F765.
131. NAKAGAWA Y., MARGOLIS HS., YOKOYAMA S., KEZDY FJ., KAISER ET., COE FL. Purification and characterization of calcium oxalate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem., 1981; 256:3936.
132. HOYER JR. Uropontin in urinary calcium stone formation. Miner Electrolyte Metab., 1995; 20 : 385.
133. CONTE.A, ROCA. P, GRASSES.F.Uric acid and its relation-skip with glycoaminoglycans in normal and stone former subjects 1989.Nephron 52:162-165
134. ASHBY RA., SLEET RJ. The role of citrate complexes in preventing urolithiasis.
Clinica Chemica Acta.,1992; 210 : 157-1.
135. ANTINOZZI PA., BROWN CM., Khan SR., PYRICH D. Inhibitory action of citrate on calcium oxalate monohydrate crystal nucleation and growth. In Proceeding of the VIIth International Symposium on Urolithiasis cairns, 24-28 aôut 1992, 115
136. SUTOR DJ., PERCIVAL JM., DOONAN S. Isolation and identification of some urinary inhibitors of calcium phosphate formation. Clin Chim Acta 1978; 89: 273-278.
137. RAYALL RL., HARNETT RM., MARSHALL VR. The effect of urine, phyrophosphate, citrate, magnesium and glycoaminoglycans on the groth and aggregation of calcium oxalate crystals in vitro, Clin Acta;1981; 112:349.
138. FLEISH H., BISAZ S. Isolation from urine of pyrophosphate, a calcification inhibitor Am J Physiol.1962; 203: 1222.
139. FLEISH H., BISAZ S. Mechanism of calcification: inhibitory of pyrophosphate.
Nature; 1962; 195:911.
140. GRASES F., RAMIS M., COSTA-BAUZA A. Effect of phytate and pyrophosphate on brushite and hydroxyapatite crystalization, comparison whith the action of other polyphosphates.Urol Res. 2000; 28:136-140
141. D.BERTRAND. Traitement urologique actuel des calculs d’infection. Carré des sciences.1999, Paris21-22 octobre.
